The Texas compounder announced the deal last week, explaining that the facility will allow it to access key regional markets.
The firm said it plans to make modifications and register the compounding facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). It also said it plans to hire 100 staff when the site is operational next year.
Further details of the deal were not disclosed.
A spokesman for the firm told us "We are not permitted to say which company QuVa is purchasing the building from."
QuVa currently operates two 503B compounding facilities. One of the facilities - in Sugarland, Texas – was acquired from Healix in August last year in a deal that also saw QuVa hire staff employed at the site.
QuVa’s other facility in Temple Texas was purchased in November when the firm acquired Unique Pharmaceuticals.
At the time QuVa said the deal was designed to increase its capacity to make sterile injectable products for hospitals
Peter Jenkins, co-founder, said: “This acquisition broadens our catalogue of available compounded products, and gives us the capability to compound preparations from API to meet supply shortages.”
The US Food and Drug Administration (FDA) introduced the facility registration rules in 2013 after 64 people in 2012 as a result of contaminated drugs produced at Massachusetts firm NECC.